Radicava manufacturer?

What is the manufacturer of the Parkinson's disease treatment Radicava?

Radicava, also known as edaravone, is a medication used to treat primary progressive multiple sclerosis and amyotrophic lateral sclerosis (ALS). It is manufactured by Mitsubishi Tanabe Pharma Corporation, in partnership with Moberg Pharma. Mitsubishi Tanabe Pharma Corporation is a Japanese pharmaceutical company headquartered in Osaka, Japan [1].

Who else supplies Radicava outside of its original patent?

In June 2020, the United States Food and Drug Administration (FDA) approved a generic version of Radicava, allowing other companies to manufacture the drug without a patent agreement. This move has opened up the market for generic versions of the medication, which could make it more accessible and affordable for patients. As a result, companies like Teva Pharmaceuticals, Sandoz, and other generic manufacturers now offer versions of edaravone, the active ingredient in Radicava [2].

Can biosimilars enter before patent expiry?

In 2020, a biosimilar version of edaravone, also referred to as a "biogeneric" or "follow-on biologic," was approved in the US, allowing other companies to produce biosimilars of Radicava. Biosimilars are not biologics in their own right but are designed to have a similar protein structure and function as the original product. However, patent laws protect original biological products, including biologics and biosimilars, which can limit market access and competition to generic versions of the drug [3].

Sources:

[1] Mitsubishi Tanabe Pharma Corporation. (n.d.). About Us. [Online] Available: https://www.mt-pharma.co.jp/en/about-us/index.html
[2] DrugPatentWatch.com. (n.d.). Edaravone. [Online] Available: https://www.drugpatentwatch.com/edaravone-patent-expiration-date/
[3] Genentech. (n.d.). Biosimilars. [Online] Available: https://www.genentech.com/our-company/science/biosimilars.html